GNPX stock forecast
Our latest prediction for Genprex, Inc.'s stock price was made on the Sept. 5, 2019 when the stock price was at 0.87$.
In the short term (2weeks), GNPX's stock price should outperform the market by 5.01%. During that period the price should oscillate between -7.35% and +16.55%.
In the medium term (3months), GNPX's stock price should outperform the market by 7.99%. During that period the price should oscillate between -16.41% and +50.45%.Get email alerts
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.75$ per share.
The book value per share is 0.84$
Three months stock forecastSept. 5, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|